ATE533513T1 - Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel - Google Patents

Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel

Info

Publication number
ATE533513T1
ATE533513T1 AT03770286T AT03770286T ATE533513T1 AT E533513 T1 ATE533513 T1 AT E533513T1 AT 03770286 T AT03770286 T AT 03770286T AT 03770286 T AT03770286 T AT 03770286T AT E533513 T1 ATE533513 T1 AT E533513T1
Authority
AT
Austria
Prior art keywords
cyclodextrin
therapeutic
methods
relates
administration
Prior art date
Application number
AT03770286T
Other languages
German (de)
English (en)
Inventor
Jianjun Cheng
Mark Davis
Kay T Khin
Original Assignee
Cerulean Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31982363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE533513(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cerulean Pharma Inc filed Critical Cerulean Pharma Inc
Application granted granted Critical
Publication of ATE533513T1 publication Critical patent/ATE533513T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44—Polyester-amides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/26—Esters containing oxygen in addition to the carboxy oxygen
    • C08F220/28—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
    • C08F220/282—Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety and containing two or more oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nanotechnology (AREA)
  • Primary Health Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Business, Economics & Management (AREA)
AT03770286T 2002-09-06 2003-09-04 Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel ATE533513T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40885502P 2002-09-06 2002-09-06
US42283002P 2002-10-31 2002-10-31
US45199803P 2003-03-04 2003-03-04
PCT/US2003/027588 WO2004022099A2 (en) 2002-09-06 2003-09-04 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto

Publications (1)

Publication Number Publication Date
ATE533513T1 true ATE533513T1 (de) 2011-12-15

Family

ID=31982363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03770286T ATE533513T1 (de) 2002-09-06 2003-09-04 Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel

Country Status (17)

Country Link
US (20) US7270808B2 (enExample)
EP (4) EP1534340B1 (enExample)
JP (4) JP2006502301A (enExample)
KR (6) KR101476067B1 (enExample)
CN (2) CN104383554B (enExample)
AT (1) ATE533513T1 (enExample)
AU (2) AU2003278764C1 (enExample)
BR (2) BRPI0314042B8 (enExample)
CA (1) CA2497792C (enExample)
CY (2) CY1112362T1 (enExample)
ES (3) ES2377318T3 (enExample)
HK (1) HK1254600A1 (enExample)
IL (2) IL234716A0 (enExample)
MX (2) MX367615B (enExample)
PT (2) PT1534340E (enExample)
TW (2) TWI422379B (enExample)
WO (1) WO2004022099A2 (enExample)

Families Citing this family (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
WO2003059988A2 (en) * 2002-01-14 2003-07-24 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
EP1534269B1 (en) * 2002-07-19 2013-10-30 The General Hospital Corporation Oxime conjugates and methods for their formation and use
JP2006502301A (ja) 2002-09-06 2006-01-19 インサート セラピューティクス インコーポレイテッド 治療剤配送のためのシクロデキストリン基材重合体
KR20050051686A (ko) * 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도
SG129240A1 (en) * 2003-01-23 2007-02-26 Agency Science Tech & Res Biodegradable copolymer and nucleic acid delivery system
JP4009721B2 (ja) * 2003-05-23 2007-11-21 独立行政法人産業技術総合研究所 イオン結合性ポリマー含有基板、該基板を含有する検出用センサー及び病原菌又は病原菌が生産する毒素の検出方法
JP5537763B2 (ja) * 2003-09-05 2014-07-02 ザ ジェネラル ホスピタル コーポレイション 放出システムとしてのポリアセタール薬物抱合体
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
US8394365B2 (en) * 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
JP5632119B2 (ja) * 2003-09-17 2014-11-26 ウェルズ ファーゴ バンク ナショナル アソシエイション 多分岐ポリマーのプロドラッグ
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
WO2005103068A2 (en) * 2004-04-23 2005-11-03 Novexin Limited Methods and kits for folding proteins in the presence of linear or branched sugar polymers
US8128954B2 (en) 2004-06-07 2012-03-06 California Institute Of Technology Biodegradable drug-polymer delivery system
US7498342B2 (en) * 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
TW200640493A (en) * 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
CA2603730A1 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
DK2395004T3 (en) * 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
US20070021380A1 (en) * 2005-07-22 2007-01-25 Leonard Wiebe Novel drug delivery compositions
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
AU2006287521A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
WO2007030574A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
CN101304992A (zh) * 2005-09-07 2008-11-12 普莱希科公司 用作ppar调节剂的1,3-二取代吲哚衍生物
EP1976546A4 (en) * 2005-12-19 2011-05-25 Capsutech Ltd CYCLODEXTRIN-CONTAINING POLYMERS AND APPLICATIONS THEREOF
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
MX2008012387A (es) 2006-03-29 2008-10-09 Novartis Ag Inhibidores selectivos de mmp basados en hidroxamato.
US20080027212A1 (en) 2006-06-28 2008-01-31 Skinner Keith K Methods and compositions for improved uptake of biological molecules
JP5042311B2 (ja) 2006-07-20 2012-10-03 ノバルティス アーゲー Ｃｅｔｐ阻害剤としてのアミノピペリジン誘導体
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
CA2669541C (en) 2006-11-30 2014-11-18 Nektar Therapeutics Al, Corporation Method for preparing a polymer conjugate
TWI528976B (zh) * 2006-12-13 2016-04-11 斯茹林製藥公司 用於醫物傳遞之以環糊精為基之聚合物
WO2008079909A1 (en) * 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
JP2010516625A (ja) * 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
MX2009008549A (es) * 2007-02-09 2009-08-18 Enzon Pharmaceuticals Inc Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
EP2489372A3 (en) 2007-03-14 2013-01-02 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
RU2523909C2 (ru) 2007-06-25 2014-07-27 Эндосайт, Инк. Конъюгаты, содержащие гидрофильные спейсеры линкеров
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP2170830B1 (en) * 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
CA2698812A1 (en) * 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
WO2009041666A1 (ja) * 2007-09-28 2009-04-02 Nanodex Inc. 葉酸修飾されたシクロデキストリン化合物、その製造方法、標的指向性薬物送達システム用の薬物送達剤、医薬組成物及び造影剤
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
PT2463282E (pt) 2007-11-05 2013-11-11 Novartis Ag Derivados de 4-benzilamino-1-carboxiacil-piperidina como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
PT2229356E (pt) 2007-12-03 2012-01-20 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
AU2009228765B2 (en) 2008-03-24 2012-05-31 Novartis Ag Arylsulfonamide-based matrix metalloprotease inhibitors
AU2009231804B2 (en) * 2008-03-31 2015-06-04 Boston Medical Center Corporation Predictive marker for topoisomerase I inhibitors
CN102037123A (zh) 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Epas1抑制剂的组合物和用途
US8158636B2 (en) * 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PE20091846A1 (es) * 2008-05-19 2009-12-16 Plexxikon Inc DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
US8110576B2 (en) * 2008-06-10 2012-02-07 Plexxikon Inc. Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
WO2009152083A1 (en) * 2008-06-10 2009-12-17 Plexxikon, Inc. 5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
EP2323628B1 (en) 2008-08-13 2022-04-13 California Institute of Technology Carrier nanoparticles and related compositions, methods and systems
US20100056555A1 (en) * 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
US20100068275A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Personalizable dosage form
US20100068153A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex vivo activatable final dosage form
US20100068283A1 (en) * 2008-09-16 2010-03-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Ex VIVO modifiable particle or polymeric material medicament carrier
LT2349346T (lt) 2008-09-23 2019-09-25 Nektar Therapeutics Kamptotecino provaistų (pvz., peg-irinotekano) metronominio dozavimo būdas
CA2738807A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US20110287036A1 (en) * 2008-11-17 2011-11-24 Riken Novel cancer targeting therapy using complex of subtance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
KR20110102420A (ko) * 2008-12-10 2011-09-16 메르사나 테라퓨틱스, 인코포레이티드 생분해성 및 생체적합성 캄토테신-중합체 접합체의 약학 제제
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
EP2401225B1 (en) 2009-02-26 2014-10-22 The Regents of The University of California A supramolecular approach for preparation of size controllable nanoparticles
KR101663339B1 (ko) 2009-03-11 2016-10-06 플렉시콘 인코퍼레이티드 Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
KR20110130463A (ko) * 2009-03-11 2011-12-05 플렉시콘, 인코퍼레이티드 Ｒａｆ 키나제의 억제를 위한 피롤로［２,３-ｂ］피리딘 유도체
KR20170058465A (ko) * 2009-04-03 2017-05-26 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
TW201041888A (en) * 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2010138802A2 (en) 2009-05-28 2010-12-02 Cornell University Compositions and their use for removing cholesterol
JP5747432B2 (ja) * 2009-05-28 2015-07-15 国立大学法人秋田大学 ２置換修飾シクロデキストリンおよびこれを用いた核酸検出方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
US20110152512A1 (en) * 2009-09-09 2011-06-23 John Ryan Cyclodextrin-based polymers for therapeutics delivery
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
EA201200486A1 (ru) * 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
US8381774B2 (en) * 2009-09-20 2013-02-26 Medtronic Vascular, Inc. Methods for loading a drug eluting medical device
AU2010315126B2 (en) * 2009-11-06 2015-06-25 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
KR20120097512A (ko) * 2009-11-18 2012-09-04 플렉시콘, 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
CN102781237A (zh) * 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
KR20120112623A (ko) * 2009-12-23 2012-10-11 플렉시콘, 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US20120004195A1 (en) * 2010-01-19 2012-01-05 Alexandra Glucksmann Cyclodextrin-based polymers for therapeutic delivery
JP2011190341A (ja) * 2010-03-15 2011-09-29 Nano Dex Kk シクロデキストリン化合物
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
AU2011255647A1 (en) * 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012044832A1 (en) * 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
SI3590949T1 (sl) 2010-10-01 2022-09-30 Modernatx, Inc. Ribonukleinske kisline, ki vsebujejo N1-metil-psevdouracil, in njihove uporabe
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US9233163B2 (en) 2010-12-28 2016-01-12 The Children's Hospital Of Philadelphia Hydrolytically releasable prodrugs for sustained release nanoparticle formulations
US8546521B2 (en) 2011-01-28 2013-10-01 Cerulean Pharma Inc. Method for fabricating nanoparticles
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
WO2012145632A1 (en) * 2011-04-21 2012-10-26 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
RU2649364C2 (ru) 2011-12-16 2018-04-02 Модерна Терапьютикс, Инк. Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
CN107929743B (zh) 2012-01-18 2023-09-01 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
HK1205156A1 (en) * 2012-01-31 2015-12-11 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
CN104244986B (zh) * 2012-03-13 2016-11-16 浦项工科大学校产学协力团 可控释的药物递送缀合物及其应用
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
EP3520821A1 (en) 2012-04-02 2019-08-07 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013158710A2 (en) 2012-04-18 2013-10-24 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014028209A1 (en) 2012-08-14 2014-02-20 The Trustees Of The University Of Pennsylvania Stabilizing shear-thinning hydrogels
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
IN2015DN04147A (enExample) 2012-10-16 2015-10-16 Endocyte Inc
WO2014070233A1 (en) 2012-10-29 2014-05-08 Boston Medical Center Corporation Brca1 mutations as predictive markers for topoisomerase i inhibitors
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
WO2014093343A2 (en) * 2012-12-10 2014-06-19 Massachusetts Institute Of Technology Multistage nanoparticle drug delivery system for the treatment of solid tumors
CN103044349B (zh) * 2012-12-13 2014-05-21 浙江大学 一种微波辅助纳米铁酸盐制备乙二胺四乙酸酐的方法
PE20151280A1 (es) 2012-12-21 2015-09-12 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones
CA2902157A1 (en) 2013-02-25 2014-08-28 University Of Rochester Nanoparticles for controlled release of anti-biofilm agents
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20140302516A1 (en) 2013-03-14 2014-10-09 University Of Washington Through Its Center For Commercialization Polymer dot compositions and related methods
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
NZ630875A (en) 2013-03-15 2017-12-22 Plexxikon Inc Heterocyclic compounds and uses thereof
CA2912568A1 (en) 2013-05-30 2014-12-04 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
ES2761587T3 (es) 2013-08-07 2020-05-20 Friedrich Miescher Institute For Biomedical Res Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
CA2923029A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3062742B1 (en) 2013-11-01 2021-12-01 Lensgen, Inc. Two-part accommodating intraocular lens device
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10653709B2 (en) * 2014-05-19 2020-05-19 North Carolina State University Methods of folding a graft copolymer with dual anticancer drugs and related applications
JP6602834B2 (ja) * 2014-06-30 2019-11-06 ターベダ セラピューティクス インコーポレイテッド 標的化コンジュゲートならびにその粒子及び製剤
WO2016011226A1 (en) 2014-07-16 2016-01-21 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20170210788A1 (en) 2014-07-23 2017-07-27 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
WO2016044067A1 (en) 2014-09-15 2016-03-24 Plexxikon Inc. Heterocyclic compounds and uses thereof
CN104274837B (zh) * 2014-09-18 2017-01-11 福格森（武汉）生物科技股份有限公司 一种尼洛替尼口服制剂
CN104311820B (zh) * 2014-09-24 2017-06-20 北京化工大学 一种基于多糖接枝聚天冬氨酸苄酯构建可降解药物载体的方法
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
TWI547308B (zh) * 2015-06-10 2016-09-01 聚和國際股份有限公司 聚電解質膠囊的製備方法及所製得的聚電解質膠囊
CN111643479B (zh) 2015-07-01 2023-10-27 加州理工学院 基于阳离子粘酸聚合物的递送系统
WO2017006279A1 (en) * 2015-07-08 2017-01-12 Aten Porus Lifesciences Cyclodextrin-polymer complexes and compostions and methods of making and using the same
ES2862191T3 (es) * 2015-07-22 2021-10-07 Nitto Denko Corp Composiciones y métodos para formas de liófilos de nanopartículas
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
CA3129180A1 (en) 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
JP7057278B2 (ja) 2015-10-28 2022-04-19 ターベダ セラピューティクス インコーポレイテッド Ｓｓｔｒ標的化コンジュゲート及び粒子並びにその製剤
CN113180886A (zh) 2015-12-01 2021-07-30 雷恩斯根公司 调节性人工晶状体装置
WO2017096361A1 (en) 2015-12-04 2017-06-08 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
MX2018008888A (es) * 2016-01-21 2019-06-13 Aten Porus Lifesciences Polimeros a base de ciclodextrina, metodos, composiciones y aplicaciones de los mismos.
WO2017176796A1 (en) 2016-04-04 2017-10-12 University Of Virginia Patent Foundation Compositions and methods for preventing and treating disease
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
EP3512868A4 (en) 2016-09-14 2020-04-15 Duke University NANOPARTICLES BASED ON TRIBLOCK POLYPEPTIDE FOR THE DELIVERY OF HYDROPHILIC DRUGS
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
WO2018057847A1 (en) 2016-09-23 2018-03-29 Duke University Unstructured non-repetitive polypeptides having lcst behavior
JP7330101B2 (ja) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びそのタンパク質コンジュゲート
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
WO2018119422A1 (en) 2016-12-22 2018-06-28 Duke University Polycationic microfibers and methods of using the same
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
CA3048785A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018178902A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11491237B2 (en) 2017-05-18 2022-11-08 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
CA3068318A1 (en) 2017-06-30 2019-01-03 Massachusetts Institute Of Technology Branched multi-functional macromonomers and related polymers and uses thereof
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULUS SENSITIVE BIOPOLYMER NETWORKS
US11319320B2 (en) 2017-11-06 2022-05-03 Snap Bio, Inc. PIM kinase inhibitor compositions, methods, and uses thereof
MX2020004691A (es) 2017-11-07 2020-08-20 Regeneron Pharma Enlazadores hidrofilicos para conjugados anticuerpo-farmaco.
JP2021503029A (ja) 2017-11-15 2021-02-04 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗菌性足場としての一酸化窒素放出性超分岐化合物およびそれに関する方法
BR112020013492A2 (pt) 2018-01-08 2020-12-08 Regeneron Pharmaceuticals, Inc. Esteroides e conjugados de anticorpo dos mesmos
US12296018B2 (en) 2018-01-26 2025-05-13 Duke University Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same
AU2019231712B2 (en) 2018-03-06 2025-04-10 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3768666A1 (en) 2018-03-20 2021-01-27 Plexxikon Inc. Compounds and methods for ido and tdo modulation, and indications therefor
US12257308B2 (en) 2018-04-30 2025-03-25 Duke University Stimuli-responsive PEG-like polymer-based drug delivery platform
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US10988491B2 (en) 2018-08-17 2021-04-27 Massachusetts Institute Of Technology Degradable polymers of a cyclic silyl ether and uses thereof
EP3902841B1 (en) * 2018-12-28 2025-01-29 The University of North Carolina at Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
US12428560B2 (en) * 2018-12-29 2025-09-30 Wacker Chemie Ag Hydrophilic cyclodextrin-containing silicone gels
WO2020160382A1 (en) * 2019-01-31 2020-08-06 Northwestern University Supramolecular photoprotection of a photosensitizer
SG11202110714VA (en) 2019-04-09 2021-10-28 Plexxikon Inc Condensed azines for ep300 or cbp modulation and indications therefor
WO2020236253A1 (en) 2019-05-20 2020-11-26 Massachusetts Institute Of Technology Boronic ester prodrugs and uses thereof
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
WO2021113625A1 (en) 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
KR20210071296A (ko) * 2019-12-06 2021-06-16 (주) 에이치엔에이파마켐 공유결합성 유기 골격체 및 폴리머를 이용한 경피전달용 복합체
US12042513B2 (en) 2020-01-10 2024-07-23 Massachusetts Institute Of Technology Proteolysis targeting chimeric molecules (PROTACs) with functional handles and uses thereof
CN111443068B (zh) * 2020-03-06 2023-06-27 天津大学 具有多重刺激响应特性的纯有机室温磷光材料及筛选方法和应用
WO2021202900A1 (en) 2020-04-02 2021-10-07 Plexxikon Inc. 1,6-naphthyridine compounds and methods for csk modulation and indications therefor
CA3177522A1 (en) 2020-04-23 2021-10-28 Opna Immuno-Oncology Sa Compounds and methods for cd73 modulation and indications therefor
CA3176237A1 (en) 2020-04-29 2021-11-04 Jack Lin Synthesis of heterocyclic compounds
NL2025818B1 (en) * 2020-06-11 2022-02-16 Umc Utrecht Holding Bv Improved adhesive drug carrier
MX2022015873A (es) * 2020-06-15 2023-03-23 Nanosynthons Llc Excipientes que proporcionan estabilización y mejora de la solubilización en agua y sus usos.
JP2023536346A (ja) 2020-08-05 2023-08-24 エリプシーズ ファーマ リミテッド シクロデキストリン含有ポリマートポイソメラーゼ阻害剤コンジュゲートおよびｐａｒｐ阻害剤を用いた癌の処置
US20230081426A1 (en) 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN112755197B (zh) * 2020-10-09 2023-01-13 黑龙江大学 一种环糊精药物包合物及其制备方法和应用
WO2022159319A2 (en) * 2021-01-19 2022-07-28 Mountain Valley Md Inc A porous aluminum nanoparticulate structure
CA3206549A1 (en) 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
CN115160454A (zh) * 2021-04-01 2022-10-11 四川大学 一种基于聚-β-环糊精与金刚烷主客体作用的超分子多醛化合物及其制备方法
CN113274541A (zh) * 2021-05-10 2021-08-20 四川大学 一种抗菌型胶原基医用材料及其制备方法
WO2022240966A1 (en) 2021-05-11 2022-11-17 Opna Immuno-Oncology Sa Compounds and methods for yap/tead modulation and indications therefor
KR20230050084A (ko) * 2021-10-07 2023-04-14 주식회사 셀진 Plga 및 약물을 함유하는 베타-사이클로덱스트린을 포함하는 약물 전달체
US20250049926A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical compositions comprising modified betacyclodextrins
WO2023147488A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
CN114470237B (zh) * 2022-03-21 2023-12-19 中国科学院长春应用化学研究所 一种类病毒结构基因载体、药物递送系统、其制备方法及其应用
CN115006549B (zh) * 2022-06-16 2024-07-05 湖南科技大学 一种粒径可控及可控降解的酸敏型交联环糊精纳米水凝胶药物递送系统的制备方法
CN115340615B (zh) * 2022-08-12 2023-05-02 同济大学 一种基于环糊精-氨基酸的荧光分子及其合成方法与应用
WO2024044570A1 (en) 2022-08-22 2024-02-29 Iambic Therapeutics, Inc. Compounds and methods for modulating her2
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
CN119345381B (zh) * 2024-12-23 2025-04-18 上海华之沃生物医药科技有限公司 替曲朵辛偶联物及其制备方法和应用

Family Cites Families (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2131201A (en) 1928-08-04 1938-09-27 Gen Motors Corp Composite clutch
US2129408A (en) 1936-07-02 1938-09-06 Arthur C Davidson Truck stabilizer
US2129401A (en) 1937-09-09 1938-09-06 Botinger Fred Flexible utility ladder
US2131208A (en) 1938-02-26 1938-09-27 Union Switch & Signal Co Remote indication apparatus
US3472835A (en) 1964-02-12 1969-10-14 American Mach & Foundry Schardinger dextrins
US3454530A (en) 1966-03-07 1969-07-08 Leslie C Case Novel polyols which are reaction products of a monoepoxide and a cyclic monoanhydride
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3654261A (en) 1968-06-27 1972-04-04 Cpc International Inc Quaternary ammonium alkoxide alkoxy polyol compounds
USRE32268E (en) 1973-03-01 1986-10-21 Strategic Medical Research Corp. Therapeutic composition and method of therapeutically treating warm blooded animals therewith
GB1390479A (en) 1973-09-05 1975-04-16 I Orch Sinteza Akademii Nauk L Pharmaceutical composition for treatment of parkinsonism
DE2843963A1 (de) 1978-10-09 1980-04-24 Merck Patent Gmbh Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin
DE2842862A1 (de) 1978-10-02 1980-04-10 Boehringer Mannheim Gmbh Verfahren zur bestimmung von ionen, polaren und/oder lipophilen substanzen in fluessigkeiten
CA1190855A (en) 1980-09-03 1985-07-23 Rolf W. Pfirrmann Treatment of osteitis
JPS58113198A (ja) * 1981-12-26 1983-07-05 Hidetoshi Tsuchida シクロデキストリンが結合したポルフイリン化合物
US4570629A (en) 1982-03-17 1986-02-18 University Of Illinois Foundation Hydrophilic biopolymeric copolyelectrolytes, and biodegradable wound dressing comprising same
JPS58167613A (ja) 1982-03-26 1983-10-03 Mitsubishi Petrochem Co Ltd 水溶性シクロデキストリン含有重合体の製造法
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
CA1208558A (en) 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4438253A (en) 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0130935B1 (fr) 1983-07-01 1987-04-15 Battelle Memorial Institute Polypeptide biodégradable et son utilisation pour le relargage progressif de médicaments
US4525495A (en) 1983-07-22 1985-06-25 The Dow Chemical Company Mineral filled composites
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
CH663951A5 (fr) 1984-10-10 1988-01-29 Nestle Sa Procede d'enrichissement selectif en acides gras polyinsatures d'un melange contenant des acides gras fractions enrichies obtenues et compositions les contenant.
US4582865A (en) 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
JPH0651725B2 (ja) 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4841081A (en) 1985-10-16 1989-06-20 Osaka Soda Co., Ltd. Method of optically resolving a racemate or a diastereomeric mixture of glycidyl compound
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
EP0258780B1 (en) 1986-09-05 1993-06-23 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
GB2197720A (en) 1986-11-20 1988-05-25 Nat Res Dev Immobilisation of polynucleotides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
EP0362290A4 (en) 1987-06-17 1991-09-25 Princess Margaret Children's Medical Research Foundation (Inc.) Cloning of mite allergens
US4877778A (en) 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
US4774329A (en) 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US4941996A (en) 1987-10-19 1990-07-17 Minnesota Mining And Manufacturing Company Inclusion complexes providing second harmonic generation
US5760015A (en) 1988-01-19 1998-06-02 The Trustees Of The University Of Pennsylvania Cyclodextrin compounds and methods of making and use thereof
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JP2614081B2 (ja) 1988-05-27 1997-05-28 大塚化学株式会社 光学活性β−ラクタム誘導体の製造法
US4887778A (en) 1988-06-01 1989-12-19 Universal Instruments Corporation Feeder drive assembly and replaceable section for tape supplying and cover peeling
JPH01319502A (ja) * 1988-06-21 1989-12-25 Showa Denko Kk シクロデキストリン誘導体及びその製造方法
HU200913B (en) 1988-07-28 1990-09-28 Ciklodextrin Kutato Fejlesztoe Process for producing infusion stock-solution containing pharmaceutically active components of bad water solubility
MY106598A (en) 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
US4902788A (en) 1988-09-29 1990-02-20 Uop Crosslinked cyclodextrins supported on porous refractory inorganic oxides
US5098793A (en) 1988-09-29 1992-03-24 Uop Cyclodextrin films on solid substrates
IT1230566B (it) 1988-10-17 1991-10-28 Vectorpharma Int Farmaci poco solubili supportati su sostanze polimeriche in forma atta all'aumento della velocita' di dissoluzione
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH03221505A (ja) 1990-01-29 1991-09-30 Toppan Printing Co Ltd シクロデキストリンポリマーの合成方法及びシクロデキストリン膜の製造方法
EP0518930A4 (en) 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
DE4009825A1 (de) 1990-03-27 1991-10-02 Consortium Elektrochem Ind Wasserunloesliche cyclodextrin-polymerisate und verfahren zu deren herstellung
US5139687A (en) 1990-05-09 1992-08-18 The Proctor & Gamble Company Non-destructive carriers for cyclodextrin complexes
JPH0425505A (ja) 1990-05-21 1992-01-29 Toppan Printing Co Ltd シクロデキストリンポリマー及びシクロデキストリン膜の製造方法
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
FR2665169A1 (fr) 1990-07-30 1992-01-31 Rhone Poulenc Chimie Composes d'inclusion de cyclodextrines enfermant des antioxydants phenoliques et leur utilisation dans les polymeres.
JPH04106101A (ja) 1990-08-27 1992-04-08 Showa Denko Kk シクロデキストリンポリマーおよびその製造方法
DE69103503T2 (de) * 1990-09-28 1995-01-05 Mercian Corp Adriamycinderivate.
JPH059205A (ja) * 1990-09-28 1993-01-19 Mercian Corp 新規なアドリアマイシン誘導体
KR920702376A (ko) * 1990-10-01 1992-09-03 후지다 히로미찌 시클로덱스트린 폴리머 및 그 폴리머를 이용한 시클로덱스트린막
KR927003647A (ko) 1990-11-30 1992-12-18 돕빵 인사쯔 가부시끼가이샤 시클로덱스트린유도체 및 시클로덱스트린 고정화 폴리머의 제조방법
AU663300B2 (en) 1990-12-06 1995-10-05 Affymetrix, Inc. Very large scale immobilized polymer synthesis
US5148854A (en) 1990-12-11 1992-09-22 Toshiba Kikai Kabushiki Kaisha Counting die cast manufactured goods
NO180605C (no) 1990-12-19 2003-08-28 Geco As Anordning til vektbelastning av streamerkabel
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
JPH06511270A (ja) 1991-09-06 1994-12-15 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション コレステロール濃度を低下させる組成物および方法
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
JPH07503943A (ja) 1991-10-29 1995-04-27 クローバー　コンソリデイテッド，リミテッド 封入及び薬剤放出に有用な架橋性の多糖類、ポリカチオン及び脂質
US6864101B1 (en) 1991-11-22 2005-03-08 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
JP2976154B2 (ja) 1991-11-27 1999-11-10 コニカ株式会社 ハロゲン化銀写真感光材料用固形処理剤
JP3221505B2 (ja) 1992-02-06 2001-10-22 日本信号株式会社 移動体の運行管理装置
US5219980A (en) 1992-04-16 1993-06-15 Sri International Polymers biodegradable or bioerodiable into amino acids
JPH05331074A (ja) 1992-05-27 1993-12-14 Nippon Oil & Fats Co Ltd 薬物運搬体
GB9211268D0 (en) 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
IT1256134B (it) 1992-09-09 1995-11-29 Luigi Boltri Sali lipofili contenenti isotopi neutron attivabili e composizioni che li contengono
US5482719A (en) 1992-10-30 1996-01-09 Guillet; James E. Drug delivery systems
CA2129108A1 (en) 1992-11-30 1994-06-09 Dirk Vetter Polymerisable carbohydrate esters, polymers therefrom and their use
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
WO1994018954A1 (en) 1993-02-22 1994-09-01 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of biologics and compositions useful therefor
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
US5840485A (en) 1993-05-27 1998-11-24 Selectide Corporation Topologically segregated, encoded solid phase libraries
TW328535B (en) 1993-07-02 1998-03-21 Novartis Ag Functional photoinitiators and their manufacture
JP3288149B2 (ja) 1993-08-05 2002-06-04 日本食品化工株式会社 シクロデキストリンポリマー及びその製造方法
RU2094059C1 (ru) 1993-08-30 1997-10-27 Московский государственный университет, химический факультет Способ транспорта нейротропных препаратов в мозг
US5616568A (en) 1993-11-30 1997-04-01 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
US5880154A (en) 1994-02-01 1999-03-09 The Board Of Regents Of The University Of Nebraska Polymeric adamantane analogues
TW307775B (en) 1994-02-15 1997-06-11 Novartis Erfind Verwalt Gmbh Unsaturated carbohydrate derivatives, polymers thereof and their use
DE699079T1 (de) 1994-03-07 1997-09-25 Dendritech Inc Bioaktive und/oder gezielte dendrimere-konjugate
JPH07316205A (ja) 1994-03-30 1995-12-05 D D S Kenkyusho:Kk シクロデキストリン誘導体
HU218280B (en) 1994-04-26 2000-07-28 Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes
US6589736B1 (en) 1994-11-22 2003-07-08 The Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5691316A (en) 1994-06-01 1997-11-25 Hybridon, Inc. Cyclodextrin cellular delivery system for oligonucleotides
US5716594A (en) 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
AU689924B2 (en) 1994-06-23 1998-04-09 Affymax Technologies N.V. Photolabile compounds and methods for their use
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5679773A (en) 1995-01-17 1997-10-21 Affymax Technologies N.V Reagants and methods for immobilized polymer synthesis and display
US5776842A (en) 1994-06-23 1998-07-07 Cellresin Technologies, Llc Cellulosic web with a contaminant barrier or trap
US5494854A (en) 1994-08-17 1996-02-27 Texas Instruments Incorporated Enhancement in throughput and planarity during CMP using a dielectric stack containing HDP-SiO2 films
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5548932A (en) * 1994-11-08 1996-08-27 Maxcess Technologies, Inc. Adjustable cable tray support system
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US5847170A (en) 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
US5728804A (en) 1995-06-02 1998-03-17 Research Corporation Technologies, Inc. Use of cyclodextrins for protein renaturation
US6667293B1 (en) 1995-09-12 2003-12-23 Hybridon, Inc. Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response
US6630351B1 (en) 1999-06-07 2003-10-07 Mirus Corporation Compositions and methods for drug delivery using pH sensitive molecules
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE19612768A1 (de) 1996-03-29 1997-10-02 Basf Ag Cyclodextringruppen enthaltende Polymere, Verfahren zu ihrer Herstellung und ihre Verwendung
JP3830198B2 (ja) 1996-03-29 2006-10-04 東光薬品工業株式会社 超分子構造高分子集合体を用いた皮膚透過性インドメタシン外用剤
JPH11514388A (ja) * 1996-04-03 1999-12-07 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア シクロデキストリン化合物ならびにその製造法および使用
DE19629494A1 (de) 1996-07-09 1998-01-15 Schering Ag Pseudopolyrotaxane
US5844030A (en) 1996-07-09 1998-12-01 Andros; Nicholas Charged ion cleaning devices and cleaning system
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
ATE234674T1 (de) 1996-11-14 2003-04-15 Affymetrix Inc Chemische amplifizierung zur synthese von musterordnungen
JPH10158195A (ja) 1996-11-28 1998-06-16 Res Inst For Prod Dev 配位結合を利用した薬物−高分子複合体製剤の調製方法
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
HUP9700632A3 (en) 1997-03-24 1999-10-28 Cyclolab Ciklodextrin Kutato F Pharmaceutical compositions containing propylamine derivative and cyclodextrine and process for producing the same
WO1998047496A2 (en) * 1997-04-18 1998-10-29 Access Pharmaceuticals, Inc. Polymer-platinum compounds
WO1998047536A1 (en) 1997-04-23 1998-10-29 University Of Otago Controlled release of ophthalmic compositions
AU749410B2 (en) 1997-04-30 2002-06-27 Regents Of The University Of Minnesota In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US6207195B1 (en) 1997-06-13 2001-03-27 The Johns Hopkins University Therapeutic nanospheres
DE19726186A1 (de) 1997-06-20 1998-12-24 Boehringer Ingelheim Int Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
JPH11100401A (ja) 1997-07-30 1999-04-13 Kikkoman Corp 環状オリゴ糖及びそれを含むレトロウイルス性疾患の予防または治療剤
US6410342B1 (en) 1997-08-19 2002-06-25 Pharmacopeia, Inc. Method and apparatus for controlled photoelution
WO1999013915A1 (en) 1997-09-15 1999-03-25 Genetic Immunity, Llc. Method of delivering genes to antigen presenting cells of the skin
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
GB9801109D0 (en) 1998-01-20 1998-03-18 Pfizer Cyclodextrin compositions
JP4503828B2 (ja) 1998-02-11 2010-07-14 ユニバーシティー オブ ヒューストン 光生成試薬を用いる化学反応および生化学反応のための方法および装置
IT1298732B1 (it) 1998-03-13 2000-02-02 Recordati Chem Pharm Composizioni farmaceutiche orali assumibili senza liquidi,contenenti complessi di inclusione
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
WO1999061062A1 (en) 1998-05-29 1999-12-02 Massachusetts Institute Of Technology Cyclodextrin complexes
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
CA2346866A1 (en) 1998-10-16 2000-04-27 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services Combination therapy with vip antagonist
AU2162700A (en) 1998-12-04 2000-06-26 California Institute Of Technology Supramolecular complexes containing therapeutic agents
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
JP2002533422A (ja) 1998-12-23 2002-10-08 ジー・ディー・サール・アンド・カンパニー 新形成の治療における併用療法としてシクロオキシゲナーゼ−２阻害剤とインテグリン拮抗剤を使用する方法
US6740643B2 (en) 1999-01-21 2004-05-25 Mirus Corporation Compositions and methods for drug delivery using amphiphile binding molecules
FR2789685B1 (fr) * 1999-02-15 2001-05-04 Univ Lille Sciences Tech Procede de fabrication de polymeres solubles et insolubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s) et polymeres solubles a base de cyclodextrine(s) et/ou de derives de cyclodextrine(s)
AUPP913999A0 (en) * 1999-03-12 1999-04-01 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
FR2792942B1 (fr) 1999-04-29 2001-06-08 Commissariat Energie Atomique Cyclodextrines amphiphiles, leur preparation et leur utilisation pour solubiliser des systemes organises et incorporer des molecules hydrophobes
JP2003501440A (ja) 1999-06-07 2003-01-14 マイラス コーポレーション 反応活性なジスルフィド結合を含む化合物
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6420378B1 (en) 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
EP1233671A4 (en) 1999-11-29 2005-11-02 Mirus Corp COMPOSITIONS AND METHODS OF DISPOSING MEDICAMENTS USING AMPHIPHILIC BINDING MOLECULARS
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
US20010041706A1 (en) 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
AU2001240024A1 (en) * 2000-03-31 2001-10-15 Supergen, Inc. Camptothecin complexes
JP2001288097A (ja) 2000-04-07 2001-10-16 Pg-Txl Co Lp 水溶性パクリタキセル誘導体
EP1301500B1 (en) 2000-06-22 2007-11-21 Nitromed, Inc. Nitrosated and nitrosylated taxanes, compositions and methods of use
US6664228B1 (en) 2000-08-10 2003-12-16 Ceramoptec Industries, Inc. Photoselective marking of biological targets
JP2005503101A (ja) 2000-08-01 2005-02-03 オレゴン ヘルス アンド サイエンス ユニバーシティ 哺乳動物のｄｎａを結合する膜結合タンパク質をコードする遺伝子およびその使用
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
WO2002057424A2 (en) 2001-01-17 2002-07-25 Zycos Inc. Nucleic acid delivery formulations
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6828392B2 (en) 2001-08-28 2004-12-07 Carlsberg A/S Hydroxy and amine functionalized resins
WO2003020305A1 (en) 2001-08-30 2003-03-13 Baylor College Of Medecine Methionine restriction for cancer therapy
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
US20030157030A1 (en) 2001-11-02 2003-08-21 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
US20030134824A1 (en) 2001-11-12 2003-07-17 Ronald Breslow Beta-cyclodextrin dimers and phthalocyanines and uses thereof
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
US6527887B1 (en) 2002-01-18 2003-03-04 Mach I, Inc. Polymeric cyclodextrin nitrate esters
EP1490090A4 (en) * 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
AU2003239121A1 (en) 2002-02-22 2003-09-09 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
US7008936B2 (en) 2002-06-14 2006-03-07 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
WO2004009664A2 (en) 2002-07-19 2004-01-29 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
EP1562627A4 (en) 2002-08-23 2006-11-02 Mclean Hospital Corp CORTICOSTEROID CONJUGATES AND ITS USES
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
JP2006502301A (ja) 2002-09-06 2006-01-19 インサート セラピューティクス インコーポレイテッド 治療剤配送のためのシクロデキストリン基材重合体
US20040047835A1 (en) 2002-09-06 2004-03-11 Cell Therapeutics, Inc. Combinatorial drug therapy using polymer drug conjugates
CA2892003A1 (en) 2002-09-06 2004-03-18 Cerulean Pharma Inc. Modified cyclodextrin ring compounds having exactly two hydroxyl moieties substituted with an amino acid for therapeutics delivery
KR20050051686A (ko) 2002-10-09 2005-06-01 인설트 테라페틱스, 인코퍼레이티드 사이클로덱스트린-기초한 재료, 조성물 및 이의 용도
EP1551425A4 (en) 2002-10-09 2006-09-20 Kosan Biosciences Inc THERAPEUTIC FORMULATIONS
CN1309763C (zh) 2002-10-31 2007-04-11 日本化药株式会社 喜树碱的高分子衍生物
EP2213738B1 (en) 2002-11-14 2012-10-10 Dharmacon, Inc. siRNA molecules targeting Bcl-2
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
TWI367096B (en) 2003-01-27 2012-07-01 Endocyte Inc Vitamin-receptor binding drug delivery conjugates and pharmaceutical compositions
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
CN1216057C (zh) 2003-03-28 2005-08-24 贵州省生物研究所 喜树碱类似物的衍生物及其制备方法
RS20160203A1 (sr) 2003-05-30 2016-10-31 Genentech Inc Tretman sa anti-vegf antitelima
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
CA2547934C (en) 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
WO2006065780A2 (en) 2004-12-15 2006-06-22 Novartis Ag Combinations of therapeutic agents for treating cancer
TW200640493A (en) 2005-02-16 2006-12-01 Insert Therapeutics Inc Cyclodextrin-based polymers for therapeutics delivery
CN105288630A (zh) 2005-02-18 2016-02-03 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
MX2007010394A (es) 2005-02-24 2008-02-19 Elan Pharma Int Ltd Formulaciones nanoparticuladas de docetaxel y analogos del mismo.
CA2603730A1 (en) 2005-03-31 2006-10-05 Calando Pharmaceuticals, Inc. Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
US20090202989A1 (en) 2005-06-28 2009-08-13 Hillan Kenneth J Egfr and kras mutations
JP4994618B2 (ja) 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US8143236B2 (en) 2005-12-13 2012-03-27 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods
US7897568B2 (en) 2006-03-03 2011-03-01 Vinay K. Singh Compositions for treatment of cancer
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
TWI528976B (zh) 2006-12-13 2016-04-11 斯茹林製藥公司 用於醫物傳遞之以環糊精為基之聚合物
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
WO2008148080A2 (en) 2007-05-24 2008-12-04 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
FR2918279B1 (fr) 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
AU2008338526A1 (en) 2007-12-14 2009-06-25 Immune Disease Institute, Inc. Treatment and prevention of HIV infection
CN102037123A (zh) 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Epas1抑制剂的组合物和用途
US20100056555A1 (en) 2008-08-29 2010-03-04 Enzon Pharmaceuticals, Inc. Method of treating ras associated cancer
US20110223241A1 (en) 2008-10-16 2011-09-15 Celator Pharmaceuticals, Inc. Combination methods and compositions
AU2010234916A1 (en) 2009-03-30 2011-10-13 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
EA201200486A1 (ru) 2009-09-15 2012-08-30 Серулин Фарма Инк. Лечение онкологических заболеваний
US20110245201A1 (en) 2009-09-15 2011-10-06 John Ryan Treatment of cancer
US20130029909A1 (en) 2009-09-15 2013-01-31 John Ryan Treatment of cancer
CN102781237A (zh) 2009-11-23 2012-11-14 天蓝制药公司 用于传递治疗剂的基于环糊精的聚合物
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2012044832A1 (en) 2010-09-30 2012-04-05 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2756309B1 (en) 2011-09-12 2015-07-22 Universiteit Gent Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer
WO2013059651A1 (en) 2011-10-21 2013-04-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bifunctional compounds
EP2903644A4 (en) 2012-10-05 2016-03-09 Cerulean Pharma Inc TREATMENT OF CANCER

Also Published As

Publication number Publication date
KR20130033467A (ko) 2013-04-03
MXPA05002444A (es) 2005-09-30
JP5586487B2 (ja) 2014-09-10
US8580244B2 (en) 2013-11-12
PT1534340E (pt) 2012-03-13
US8518388B2 (en) 2013-08-27
KR20180004322A (ko) 2018-01-10
TW201221132A (en) 2012-06-01
KR20050038039A (ko) 2005-04-25
US20210128516A1 (en) 2021-05-06
CN102516417B (zh) 2014-12-10
US20130039880A1 (en) 2013-02-14
US8399431B2 (en) 2013-03-19
US20150165055A1 (en) 2015-06-18
US20120065368A1 (en) 2012-03-15
AU2009251190B2 (en) 2012-08-09
EP2277551A3 (en) 2011-11-23
EP2402036B1 (en) 2018-02-14
AU2003278764A1 (en) 2004-03-29
US7270808B2 (en) 2007-09-18
US20130196945A1 (en) 2013-08-01
CN102516417A (zh) 2012-06-27
US8404662B2 (en) 2013-03-26
US20140044669A1 (en) 2014-02-13
JP2006502301A (ja) 2006-01-19
PT2277551E (pt) 2013-08-22
TWI422379B (zh) 2014-01-11
US20130165405A1 (en) 2013-06-27
BR122012021252B1 (pt) 2018-07-10
BRPI0314042B1 (pt) 2020-02-11
EP1534340A2 (en) 2005-06-01
CN104383554B (zh) 2018-06-08
AU2003278764B2 (en) 2010-02-04
EP3332811A1 (en) 2018-06-13
HK1254600A1 (en) 2019-07-26
US8580243B2 (en) 2013-11-12
JP2014167022A (ja) 2014-09-11
US8475781B2 (en) 2013-07-02
CY1114941T1 (el) 2016-12-14
US20170369651A1 (en) 2017-12-28
KR20140070676A (ko) 2014-06-10
CY1112362T1 (el) 2015-12-09
US8389499B2 (en) 2013-03-05
CN104383554A (zh) 2015-03-04
US20130203700A1 (en) 2013-08-08
KR20160106223A (ko) 2016-09-09
HK1151467A1 (en) 2012-02-03
US20120283214A1 (en) 2012-11-08
ES2377318T3 (es) 2012-03-26
HK1072202A1 (en) 2005-08-19
JP2012082220A (ja) 2012-04-26
US20130129665A1 (en) 2013-05-23
US8314230B2 (en) 2012-11-20
WO2004022099A3 (en) 2004-10-28
US20130131013A1 (en) 2013-05-23
IL234715A0 (en) 2014-11-30
KR101268258B1 (ko) 2013-05-31
US8603454B2 (en) 2013-12-10
EP2402036A1 (en) 2012-01-04
JP2011080089A (ja) 2011-04-21
CA2497792A1 (en) 2004-03-18
AU2009251190A1 (en) 2010-01-21
US8580242B2 (en) 2013-11-12
JP5681646B2 (ja) 2015-03-11
AU2003278764C1 (en) 2010-09-16
EP2277551B1 (en) 2013-05-08
WO2004022099A2 (en) 2004-03-18
BR0314042A (pt) 2005-07-05
BRPI0314042B8 (pt) 2021-05-25
US20120178711A1 (en) 2012-07-12
US20080058427A1 (en) 2008-03-06
EP2277551A2 (en) 2011-01-26
ES2666694T3 (es) 2018-05-07
MX367615B (es) 2019-08-28
CA2497792C (en) 2014-08-05
TW200423947A (en) 2004-11-16
US8680202B2 (en) 2014-03-25
US20140288023A1 (en) 2014-09-25
US20130190450A1 (en) 2013-07-25
US8110179B2 (en) 2012-02-07
US20130156721A1 (en) 2013-06-20
IL234716A0 (en) 2014-11-30
ES2417324T3 (es) 2013-08-07
TWI366464B (en) 2012-06-21
US20120289480A1 (en) 2012-11-15
JP5934743B2 (ja) 2016-06-15
US20120301424A1 (en) 2012-11-29
US8252276B2 (en) 2012-08-28
US20040077595A1 (en) 2004-04-22
KR101857900B1 (ko) 2018-05-14
AU2009251190C1 (en) 2013-03-14
KR102008768B1 (ko) 2019-08-08
EP1534340B1 (en) 2011-11-16
BR122012021252B8 (pt) 2021-05-25
KR20120104412A (ko) 2012-09-20
KR101476067B1 (ko) 2014-12-23
US8609081B2 (en) 2013-12-17
US9550860B2 (en) 2017-01-24

Similar Documents

Publication Publication Date Title
ATE533513T1 (de) Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
WO2006089007A3 (en) Cyclodextrin-based polymers containing photocleavable linkers for drug delivery
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
CY1113258T1 (el) Συμπλοκο φυλλικου- βινβλαστινης ως φαρμακο
Kim et al. NONOates–polyethylenimine hydrogel for controlled nitric oxide release and cell proliferation modulation
Banskota et al. Genetically encoded stealth nanoparticles of a Zwitterionic polypeptide-paclitaxel conjugate have a wider therapeutic window than Abraxane in multiple tumor models
Bonzi et al. Novel pullulan bioconjugate for selective breast cancer bone metastases treatment
ATE368066T1 (de) Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff
WO2005058367A3 (en) Pegylated small molecules
EP1988910A4 (en) ACRYLOYLOXYETHYLPHOSPHORYLCHOLIN-CONTAINING POLYMER CONJUGATES AND THEIR PREPARATION
WO2006060533A3 (en) Conjugates of 1, 8-bis-naphthalimides with an antibody
EP1430061A4 (en) INCLUSION COMPOUND CONTAINING CUCURBITURIL DERIVATIVES AS RECEPTOR MOLECULE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
ATE345775T1 (de) Zusammensetzungen zur verabreichung von arzneimittelkombinationen
MA32394B1 (fr) Composes pegyles d'insuline lispro
Chu et al. Systemic delivery and biodistribution of cisplatin in vivo
Jin et al. A unique class of duocarmycin and CC-1065 analogues subject to reductive activation
ATE342054T1 (de) Verfahren und zusammansetzung zur behandlung von krebs
Kashiwazaki et al. Synthesis and biological properties of highly sequence-specific-alkylating N-methylpyrrole–N-methylimidazole polyamide conjugates
Dichwalkar et al. Omega‐3 fatty acid grafted PAMAM‐Paclitaxel conjugate exhibits enhanced anticancer activity in upper gastrointestinal cancer cells
WO2006073430A3 (en) Therapeutic delivery system comprising a high molecular weight peg-like compound
WO2004113383A3 (en) Pegylated soluble gp130-dimers useful as a medicament
FR2900404B1 (fr) Nouveaux derives d'imidazoles, leur preparation et leur utilisation en tant que medicament
EA201070193A1 (ru) Лечение детских опухолей
JP2002538080A (ja) 抗癌剤及び少なくとも一つのペプチドを含む医薬組成物
ATE488243T1 (de) Pharmazeutische zusammensetzung zur injektion, insbesondere zur gezielten lokalen anwendung